JOP20200252B1 - مركبات مساعدة لعامل تمايز النمو 15 وطرق استخدامها - Google Patents

مركبات مساعدة لعامل تمايز النمو 15 وطرق استخدامها

Info

Publication number
JOP20200252B1
JOP20200252B1 JOP/2020/0252A JOP20200252A JOP20200252B1 JO P20200252 B1 JOP20200252 B1 JO P20200252B1 JO P20200252 A JOP20200252 A JO P20200252A JO P20200252 B1 JOP20200252 B1 JO P20200252B1
Authority
JO
Jordan
Prior art keywords
compounds
methods
same
differentiation factor
agonist compounds
Prior art date
Application number
JOP/2020/0252A
Other languages
English (en)
Inventor
Victor H Obungu
Richard Todd Pickard
Malgorzata Donata Gonciarz
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of JOP20200252A1 publication Critical patent/JOP20200252A1/ar
Application granted granted Critical
Publication of JOP20200252B1 publication Critical patent/JOP20200252B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير مركبات في هذه الوثيقة التي تحث على فقدان الوزن والتي تعالج مرض السكري، اختلال الشحوم في الدم، NASH و/أو السمنة. كما يتم توفير تركيبات صيدلية تحتوي على مثل هذه المركبات والاستخدامات العلاجية لتلك المركبات والتركيبات، حيث تعمل هذه المركبات كعوامل مساعدة لـ GDF15 ممتدة المفعول وخصائص مفيدة أخرى.
JOP/2020/0252A 2018-04-06 2019-03-29 مركبات مساعدة لعامل تمايز النمو 15 وطرق استخدامها JOP20200252B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862653759P 2018-04-06 2018-04-06
PCT/US2019/024756 WO2019195091A1 (en) 2018-04-06 2019-03-29 Growth differentiation factor 15 agonist compounds and methods of using the same

Publications (2)

Publication Number Publication Date
JOP20200252A1 JOP20200252A1 (ar) 2020-10-04
JOP20200252B1 true JOP20200252B1 (ar) 2023-09-17

Family

ID=66630339

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0252A JOP20200252B1 (ar) 2018-04-06 2019-03-29 مركبات مساعدة لعامل تمايز النمو 15 وطرق استخدامها

Country Status (29)

Country Link
US (1) US11104711B2 (ar)
EP (1) EP3774860B1 (ar)
JP (1) JP7064618B2 (ar)
KR (1) KR102501922B1 (ar)
CN (1) CN112004821B (ar)
AR (1) AR115021A1 (ar)
AU (1) AU2019248535B2 (ar)
BR (1) BR112020017256A2 (ar)
CA (1) CA3096375C (ar)
CL (1) CL2020002564A1 (ar)
CO (1) CO2020012403A2 (ar)
CR (1) CR20200454A (ar)
DO (1) DOP2020000157A (ar)
EA (1) EA202092084A1 (ar)
EC (1) ECSP20062930A (ar)
ES (1) ES2937049T3 (ar)
IL (1) IL276980A (ar)
JO (1) JOP20200252B1 (ar)
MA (1) MA52228A (ar)
MX (1) MX2020010370A (ar)
NZ (1) NZ767242A (ar)
PE (1) PE20212133A1 (ar)
PH (1) PH12020551656A1 (ar)
SA (1) SA520420287B1 (ar)
SG (1) SG11202009853VA (ar)
TW (1) TWI724392B (ar)
UA (1) UA127545C2 (ar)
WO (1) WO2019195091A1 (ar)
ZA (1) ZA202005385B (ar)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2832581C (en) 2011-04-08 2022-08-23 Yumei Xiong Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EP3763734A1 (en) 2013-07-31 2021-01-13 Amgen Inc. Growth differentiation factor 15 (gdf-15) constructs
CN111954537A (zh) 2018-04-09 2020-11-17 美国安进公司 生长分化因子15融合蛋白
US20230210950A1 (en) 2019-10-04 2023-07-06 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
CN114555792A (zh) 2019-10-15 2022-05-27 伊莱利利公司 重组改造的、脂肪酶/酯酶缺陷型哺乳动物细胞系
WO2023025129A1 (zh) 2021-08-24 2023-03-02 广东东阳光药业有限公司 Gdf15融合蛋白及其用途
CN116478298A (zh) 2021-12-31 2023-07-25 广东东阳光药业有限公司 Glp-1和gdf15的融合蛋白及其用途
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
CN118580334A (zh) * 2023-03-03 2024-09-03 北京志道生物科技有限公司 一种多肽分子

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
WO2005113585A2 (en) 2004-05-20 2005-12-01 Acceleron Pharma Inc. Modified tgf-beta superfamily polypeptides
US20060074225A1 (en) 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
EP2571510B1 (en) * 2010-05-21 2018-08-08 XL-protein GmbH Biosynthetic proline/alanine random coil polypeptides and their uses
AU2012212047A1 (en) * 2011-02-03 2013-08-22 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
WO2013113008A1 (en) 2012-01-26 2013-08-01 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
EP2830646B1 (en) 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
EP2934584B1 (en) * 2012-12-21 2020-02-19 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
JP6272907B2 (ja) 2013-01-30 2018-01-31 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害の処置における組成物及び使用方法
EP3763734A1 (en) 2013-07-31 2021-01-13 Amgen Inc. Growth differentiation factor 15 (gdf-15) constructs
IL243690B (en) 2013-07-31 2022-09-01 Amgen Inc Stabilization of polypeptides involving fc
WO2015198199A1 (en) 2014-06-23 2015-12-30 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof.
EP3851445A1 (en) 2014-06-23 2021-07-21 Novartis AG Site specific protein modifications
US9272019B2 (en) 2014-06-24 2016-03-01 Novo Nordisk A/S MIC-1 fusion proteins and uses thereof
KR20170065026A (ko) 2014-07-30 2017-06-12 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애 치료용으로 이용되는 조성물 및 방법
JP6663428B2 (ja) 2014-10-30 2020-03-11 アクセルロン ファーマ， インコーポレイテッド Ｇｄｆ１５ポリペプチドを使用する、赤血球を増加させるための方法および組成物
MY186702A (en) 2014-10-31 2021-08-11 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
WO2016131893A1 (en) 2015-02-18 2016-08-25 Medimmune Limited Incretin fusion polypeptides
WO2016161100A1 (en) 2015-04-02 2016-10-06 Janssen Biotech, Inc. Protoxin-ii variants and methods of use
EP3393494A1 (en) 2015-12-22 2018-10-31 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
US11105818B2 (en) 2016-01-15 2021-08-31 Novo Nordisk A/S MIC-1 receptor and uses thereof
BR112018076290A2 (pt) 2016-02-29 2019-11-12 Huawei Tech Co Ltd método de otimização de video, equipamento do usuário, dispositivo de rede e meio legível por computador
EP3423094A4 (en) 2016-02-29 2019-11-06 Eli Lilly and Company GFRAL RECEPTOR THERAPIES
US20170299608A1 (en) 2016-03-04 2017-10-19 Ngm Biopharmaceuticals, Inc. Compositions and methods for modulating body weight
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof

Also Published As

Publication number Publication date
WO2019195091A1 (en) 2019-10-10
AU2019248535B2 (en) 2021-09-02
AU2019248535A1 (en) 2020-09-10
PH12020551656A1 (en) 2021-07-26
US20190309033A1 (en) 2019-10-10
KR102501922B1 (ko) 2023-02-23
ZA202005385B (en) 2022-09-28
EA202092084A1 (ru) 2021-01-27
MA52228A (fr) 2021-02-17
US11104711B2 (en) 2021-08-31
CN112004821B (zh) 2024-01-02
CL2020002564A1 (es) 2021-01-29
BR112020017256A2 (pt) 2020-12-22
JP7064618B2 (ja) 2022-05-10
EP3774860B1 (en) 2022-12-28
SG11202009853VA (en) 2020-11-27
CN112004821A (zh) 2020-11-27
JOP20200252A1 (ar) 2020-10-04
SA520420287B1 (ar) 2024-03-17
MX2020010370A (es) 2021-01-08
DOP2020000157A (es) 2020-09-15
NZ767242A (en) 2024-07-05
CO2020012403A2 (es) 2020-10-30
UA127545C2 (uk) 2023-10-04
CR20200454A (es) 2020-11-18
ES2937049T3 (es) 2023-03-23
IL276980A (en) 2020-10-29
AR115021A1 (es) 2020-11-18
JP2021517584A (ja) 2021-07-26
CA3096375A1 (en) 2019-10-10
PE20212133A1 (es) 2021-11-05
TWI724392B (zh) 2021-04-11
TW201946661A (zh) 2019-12-16
EP3774860A1 (en) 2021-02-17
ECSP20062930A (es) 2020-11-30
KR20200128091A (ko) 2020-11-11
CA3096375C (en) 2023-09-12

Similar Documents

Publication Publication Date Title
PH12020551656A1 (en) Growth differentiation factor 15 agonist compounds and methods of using the same
GEP20207158B (en) Amide-substituted pyridinyltriazole derivatives and uses thereof
MX2021007184A (es) Formas cristalinas del derivado de 4-pirimidinsulfamida aprocitentan.
PH12020551304A1 (en) Novel crystalline forms
NZ734400A (en) Amide compounds as 5-ht4 receptor agonists
MX2020006191A (es) Bacteriocinas terapeuticas.
MX2020005841A (es) Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6.
WO2018178243A3 (en) Dihydrotetrabenazine for use in the treatment a movement disorder
MX2021002916A (es) Pirfenidona enriquecida con deuterio y métodos para su uso.
MX2020013208A (es) Composiciones herbicidas.
MY200161A (en) Bacteria for targeting tumors and treating cancer
PH12021550122A1 (en) Solubilized apyrases, methods and use
PH12019501252A1 (en) Compositions and methods related to pyridinoylpiperidine 5-htif agonists
MX2020003185A (es) Nuevos compuestos heterociclicos.
MX2020013209A (es) Composiciones herbicidas.
MX2021015333A (es) Combinaciones de inhibidores para el tratamiento de enfermedades relacionadas con la expresion de dux4.
MX2019009293A (es) Compuestos, composiciones y usos de los mismos para la mejoria de trastornos oseos.
MX2019008535A (es) Agonista del ppar gamma para el tratamiento de la enfermedad de huntington.
ZA202103209B (en) Monohydrate potassium salt of a thienopyridone derivative and its preparation process
MX2020008082A (es) Compuestos y composiciones para el tratamiento del dolor.
EA202190045A1 (ru) Составы/композиции, содержащие ибрутиниб
EA202090432A1 (ru) Новые соединения, активирующие путь nrf2
JOP20180070B1 (ar) مثبطات إنزيم كيناز بروتين يتفاعل مع مستقبل 1
MX2019001981A (es) Agonista de ppary para el tratamiento de trastornos oseos.